| Autor: |
Tan, Joanne L. C., Wellard, Cameron, Moore, Elizabeth M., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Harrison, Simon James, McDonald, Emma‐Jane, Ho, P. Joy, Prince, H. Miles, Augustson, Bradley M., Campbell, Philip, McQuilten, Zoe K., Wood, Erica M., Spencer, Andrew |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Jan2023, Vol. 200 Issue 2, pe17-e21, 5p |
| Abstrakt: |
(C, D) Patient OS and PFS according to the R2ISS scoring in the R-ISS II cohort only. Keywords: cancer cytogenetics; myeloma; prognostic factors EN cancer cytogenetics myeloma prognostic factors e17 e21 5 01/16/23 20230115 NES 230115 To evaluate the performance of the second revision of the International Staging System 2 (R2ISS)[1] in a real-world cohort, we applied the scoring system to patients with newly-diagnosed multiple myeloma (NDMM) in the Myeloma and Related Diseases Registry (MRDR). The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text